Senior Manager - Quality Management, Training, & Compliance
About the job
- A bachelor's degree or equivalent in a health-related field, such as Medical, Scientific, Nursing, or Pharmacy, is preferred.
- At least 7 years of experience in the pharmaceutical industry, preferably in development operations or quality management.
- Demonstrated ability to lead and promote projects by inspiring and involving stakeholders.
- Strong understanding of Quality by Design principles, clinical quality risk management processes, risk-based monitoring, and trial oversight as required by ICH E6 R3.
- English communication skill, TOEIC score of 850, or equivalent capability.
- Broad knowledge of global processes and Chinese local regulatory requirements related to clinical studies.
- Ability to lead GCP inspection readiness activities and support global health authority inspections.
- Strong knowledge management, project management, and change management skills.
- Strong data insights and analytical skills to identify trends and drive quality and process improvements.
- Ability to pursue improvements, consider other people's perspectives, address issues collaboratively, and communicate with other functional areas to advance the business.
- Establish a sophisticated Quality Management framework in China R&D comprising quality elements such as processes, issue management, risk management, and knowledge management.
- Ensure clinical studies in China are conducted with high quality and in compliance with regulatory requirements and standard procedures by adopting the Quality Management framework.
- Exercise leadership over discussions regarding quality in China and contribute to maintaining a high level of quality.
- Develop, maintain, and oversee the quality system and associated strategy, processes, tools, and technologies.
- Perform local business process management aligned with global and local regulatory requirements.
- Lead impact assessment discussions about new or updated local regulations and Global QSDs in collaboration with impact assessment team members.
- Identify training needs based on data-driven decisions, and plan and provide instructor-led training from a Quality Management perspective for China R&D and/or global audiences as applicable.
- In consultation with China R&D leadership, review and refine the training curriculum for local roles in the Learning Management System.
- Advise China R&D on global and local clinical processes, procedural documents, international guidelines such as ICH-GCP, industry standards, and local regulations.
- Explore more efficient ways to improve quality and implement improvements with stakeholders through process management, training, and other quality activities.
- Lead audit response management and review quality issues and audit or inspection CAPAs to ensure suitability.
- Experience in development operations or quality management is preferred.
- A bachelor's degree or equivalent in a health-related field, such as Medical, Scientific, Nursing, or Pharmacy, is preferred.
About the company
AbbVie is a global biopharmaceutical company that develops and sells medicines to treat serious health conditions. Its portfolio spans immunology, oncology, virology, neuroscience, and aesthetics, with products designed to modulate the immune system, target disease pathways, or support medical aesthetics. AbbVie compounds its products through a heavy emphasis on research and development, investing billions to build a steady pipeline of new therapies. Its medicines are brought to market by selling to healthcare providers, hospitals, and clinics, and in some cases directly to patients via prescriptions. The company differentiates itself through a wide, globally distributed product line, substantial R&D investment, and a commitment to sustainability and patient care, including science-based targets. AbbVie’s goal is to improve patient outcomes by delivering effective treatments for unmet medical needs while pursuing long-term, responsible growth across healthcare markets.
Company Size
10,001+
Company Stage
IPO
Headquarters
North Chicago, Illinois
Founded
1888
Get referred to AbbVie
See people who can refer or advise you
Simplify's Take
What believers are saying
- Apogee acquisition closed in 2026, expanding AbbVie’s immunology pipeline beyond Skyrizi and Rinvoq.
- EU approvals for RINVOQ and EPKINLY in September 2026 broaden ex-U.S. revenue.
- JUVMO launches in October 2026, adding a fresh neuroscience revenue line.
What critics are saying
- Humira, Skyrizi, and Rinvoq concentration keeps AbbVie exposed if immunology growth slows in 2027.
- Niaspan antitrust MDL and Biocell ALCL settlements carried $1.7 billion litigation accrual by June 2026.
- Generic ubrogepant and atogepant suits threaten Ubrelvy and Qulipta exclusivity within years.
What makes AbbVie unique
- Skyrizi and Rinvoq anchor AbbVie’s post-Humira immunology franchise across 11 EU RINVOQ indications.
- JUVMO’s September 28, 2026 FDA approval gives AbbVie first-in-class Parkinson’s D1/D5 therapy.
- AbbVie pairs blockbuster cash flows with Apogee, Iambic, and Valkai deal-making.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Remote Work Options
Flexible Work Hours
Professional Development Budget
Growth & Insights and Company News
6 month growth
4%1 year growth
5%2 year growth
5%A Motley Fool comparison of AbbVie and Novo Nordisk concludes AbbVie is the better long-term buy in 2026, even though Novo looks cheaper. AbbVie's 2025 revenue rose about 8.6% to $61.2 billion, but net income was $4.2 billion. Novo Nordisk's revenue grew 6.4% to $46.3 billion, with net income of $15.3 billion. Novo trades at 11.7 times forward earnings against AbbVie's 20.2. Analysts expect Novo's 2026 sales to fall about 3% on pricing pressure and rivalry from Eli Lilly. AbbVie is forecast to grow net income to $14.6 billion on $67.2 billion in sales, helped by its $10.9 billion Apogee Therapeutics deal and its Skyrizi and Rinvoq drugs.
AbbVie shares have climbed to $281.12, up 9.33% in a month and 22.59% so far this year, after a run of clinical and regulatory news. Total shareholder return is 25.85% over one year. The news includes Phase 3 Crohn's disease results for SKYRIZI and RINVOQ, and FDA Breakthrough Therapy Designations for Temab-A in colorectal and lung cancer. AbbVie also released early obesity data for ABBV-295 and Phase 2 atopic dermatitis results for zumilokibart. Simply Wall St's most followed narrative puts fair value at $278.61, leaving the stock 1% overvalued. Its discounted cash flow model estimates $497.77, which would put the shares about 43.5% below fair value. Risks include tighter drug price pressure and faster than expected competition for Skyrizi and Rinvoq.
A comparison of AbbVie and Eli Lilly favours Eli Lilly for long-term investors, driven by its strong weight-loss and diabetes drug franchise. Lilly's 2025 revenue rose 44.7% to $65.2 billion, with net income of $20.6 billion. AbbVie's revenue grew 8.6% to $61.2 billion, with net income of $4.2 billion, as Skyrizi and Rinvoq replace ageing Humira sales. Lilly trades at a forward price-to-earnings ratio of 33.1x, against 19.8x for AbbVie. Lilly expects 2026 revenue of up to $85.2 billion, helped by Zepbound, Mounjaro and a new pill, Foundayo. AbbVie forecasts 2026 sales of $67.2 billion and net income of $14.6 billion. It is also acquiring Apogee Therapeutics.
S&P 500 stock AbbVie share: This is how much profit an investment in AbbVie 10 years ago would have generated. October 12, 2026, 4:00 p.m. Invested in AbbVie years ago: This is how much investors would have earned. Exactly 10 years ago today, trading in the AbbVie share took place on the NYSE. The stock ended the day at USD 61.21. With a USD 100 investment 10 years ago, investors would now have 1.634 AbbVie shares in their portfolio. Calculated using the most recent closing price from October 9, 2026 (USD 276.47), the investment would now be worth USD 451.67. That means the value of the original investment would have increased by 351.67 percent. The market value of AbbVie recently amounted to USD 487.20 billion. Please note that stock splits and dividend payments are not taken into account in the above calculation. finanzen.net editorial team Selected leveraged products on AbbVie. With knock-outs, speculative investors can participate disproportionately in price movements. Simply select the desired leverage and we will show you suitable open-end products on AbbVie. | Name | Leverage | KO | Issuer | | Mini Future Long on AbbVie | 4.72 | 239.26 | Morgan Stanley | | Turbo Long on AbbVie | 4.60 | 219.21 | Morgan Stanley | | Mini Future Long on AbbVie | 4.51 | 234.17 | Morgan Stanley | | Turbo Long on AbbVie | 4.31 | 215.06 | Morgan Stanley | | Turbo Long on AbbVie | 4.05 | 210.62 | Morgan Stanley | You can obtain the base prospectus as well as the final terms and the key information documents here: MR42P0, MR2ECS, MR42NZ, MR14JZ, MN9YRD. Please also note the further information** on this advertisement. Risk notice: On average, 7 out of 10 retail investors suffer losses when trading turbo certificates. Turbo certificates are highly risky products and are not suitable for long-term investment strategies.
AbbVie's dividend yield has fallen to about 2.6%, its lowest since early 2018. The drop comes from a share price that has risen faster than the dividend, not from any cut. The drugmaker has raised its dividend for 54 consecutive years, including its time as part of Abbott Labs. The payout is up almost 333% since 2013, while the stock has gained roughly 676%. Growth looks set to continue. Humira's successors, Skyrizi and Rinvoq, are on track for combined 2026 sales of over $29 billion, against Humira's peak of about $22 billion in 2021. If dividend growth matches the past five years' pace, yield on cost could top 4.6% within 10 years. Consensus analyst targets imply only about 5% upside over 12 months.